Condition
Squamous Cell Cancer of Head and Neck
Total Trials
3
Recruiting
0
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
P 1 (2)
P 2 (1)
Trial Status
Unknown1
Completed1
Active Not Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT02644369Phase 2Active Not RecruitingPrimary
Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors
NCT04504669Phase 1Completed
First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours
NCT05780307Phase 1Unknown
IMM2520, a PD-L1 and CD47 Bispecific Antibody in Patients With Advanced Solid Tumors
Showing all 3 trials